CD20在B细胞前体急性淋巴细胞白血病中的表达
Expression of CD20 in B Cell Precursor Acute Lymphoblastic Leukemia.
作者信息
Kumar Jeevan, Khan Afaq Ahmad, Saraf Amrita, Bhargava Manorama
机构信息
Department of Hematology, Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi, 110060 India.
出版信息
Indian J Hematol Blood Transfus. 2014 Mar;30(1):16-8. doi: 10.1007/s12288-012-0216-1. Epub 2012 Dec 6.
CD20 is a B cell differentiation antigen with variable expression in B cell precursor acute lymphoblastic leukemia (BCP-ALL). The significance of CD20 expression has been evaluated in BCP-ALL with conflicting results. There is paucity of data regarding CD 20 expression in BCP-ALL in Indian patients. We retrospectively analyzed 100 patients of BCP-ALL for CD20 expression. CD20 positivity was defined as expression of CD20 to be more than or equal to 20 % in the blast population. 62 % patients expressed CD20 while 38 % patients were negative for CD20. The positivity ranged from negative to dim (35.5 % patients), moderately bright (19.3 % patients) to bright (45.2 % patients). Additional prospective studies are needed to determine the optimal use of rituximab in treatment of CD20-positive BCP-ALL.
CD20是一种B细胞分化抗原，在B细胞前体急性淋巴细胞白血病（BCP-ALL）中表达可变。CD20表达的意义在BCP-ALL中已得到评估，但结果相互矛盾。关于印度患者BCP-ALL中CD20表达的数据很少。我们回顾性分析了100例BCP-ALL患者的CD20表达情况。CD20阳性定义为原始细胞群中CD20表达大于或等于20%。62%的患者表达CD20，而38%的患者CD20呈阴性。阳性范围从阴性到弱阳性（35.5%的患者）、中等强度阳性（19.3%的患者）到强阳性（45.2%的患者）。需要进一步的前瞻性研究来确定利妥昔单抗在治疗CD20阳性BCP-ALL中的最佳应用。
Zotero 插件